


# IMPORTANT UPDATE ON COMPOUNDED TIRZEPATIDE AND YOUR WEIGHT LOSS JOURNEY

## HIGHLIGHT

The U.S. Food and Drug Administration (FDA) has announced that compounding pharmacies must cease production of Tirzepatide by March 19, 2025. This decision follows the resolution of the national shortage of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) medications, leading the FDA to reinforce its guidelines on compounded versions of these drugs.

If you have been using a compounded version of Tirzepatide or considering it for weight management or blood sugar control, you may be wondering how this decision affects your treatment. We outline what this transition means for you and how we plan to ensure a seamless shift in your care.



## WHAT THIS MEANS FOR YOU

- Your treatment will continue uninterrupted. Our priority is to ensure that no dosages are missed, and we will work closely with you on this transition.
- Compounded medication remains available for now. While compounded Tirzepatide will no longer be an option after the deadline, there is currently ample supply, which remains a more cost-effective alternative.
- A transition to brand-name Zepbound is expected. Once compounded options are no longer available, we will transition to the brand-name version, Zepbound, at a higher cost.
- We will facilitate access to the most affordable Zepbound options. When the transition occurs, we will utilize Lilly Direct Pharmacy to ensure you receive the most cost-effective version. The vial with a syringe is a more affordable alternative compared to the pen, offering the same effectiveness at a lower price:
  - Vial & syringe: Approximately \$400-\$700 per dose
  - Pen injector: Approximately \$1,000-\$2,000 per dose
  - Note: The cost-effective vial version is not available at local pharmacies, which is why we will transition to a mail-order system when necessary.

## HOW TO PREPARE FOR THE TRANSITION

- **Stay informed:** We encourage you to carefully review this update and be aware of the upcoming changes.
- **Attend your monthly follow-ups:** Regular check-ins with your provider are essential to ensure your treatment plan remains optimized and any adjustments are made smoothly.
- **Direct all clinical questions to your provider:** Our staff is not equipped to discuss FDA regulations, medication changes, pricing, or dosage adjustments. These concerns should be addressed directly with your clinician.
- **Expect a personalized transition timeline:** The switch to Zepbound will depend on individual factors such as dosage availability, financial considerations, and medical needs.

## YOUR HEALTH IS IN YOUR HANDS

While medication plays a key role in weight management, long-term success relies on a comprehensive approach that includes nutrition, exercise, and stress management. This journey is about empowering you to take control of your health, and we are here to support you every step of the way.

## NEXT STEPS

- Prepare any questions you may have and discuss them with your provider at your next appointment.
- Understand that our support staff cannot provide medical guidance on this transition. All medication-related inquiries should be addressed with your clinician.

**We understand that this unexpected news may cause concern, but please rest assured that we are committed to making this transition as smooth as possible. Thank you for entrusting us with your care—we are dedicated to ensuring your continued success on your health journey.**